ResearchPod Summary
Researchers studying HIV-1 latency have historically relied on replication-defective viruses to avoid the complexities of viral spread in culture. However, these models often fail to capture the full nuances of the HIV-1 life cycle, particularly the role of accessory genes that influence immune evasion and viral reactivation. This study aimed to develop a more physiologically relevant in vitro model using replication-competent HIV-1 in primary central memory CD4+ T cells (TCM), mirroring the conditions of patients on antiretroviral therapy (ART).
The authors utilized cultured TCM cells derived from naive CD4+ T cells. These cells were infected with replication-competent HIV-1 (NL4-3 strain) and subsequently treated with ART to suppress active viral replication. To address the challenge of distinguishing latently infected cells from the background of productively infected cells, the researchers exploited the fact that HIV-1 downregulates the CD4 receptor during productive infection. By using magnetic beads to isolate cells expressing high levels of surface CD4, they successfully enriched for a population containing uninfected and latently infected cells while excluding the majority of productively infected cells. They further validated this approach using a reporter virus (HIV-1 NLENG1-IRES) that expresses GFP, allowing for high-throughput detection of viral reactivation.
The model successfully generated latently infected cells that could be reactivated using various latency-reversing agents (LRAs), including PKC agonists like bryostatin-1 and ingenol 3,20-dibenzoate, as well as SAHA and PAM3CSK4. The researchers observed a predictable, linear correlation between the frequency of productive infection and the resulting latent reservoir, suggesting the model is robust for testing LRA efficacy. Furthermore, because the virus is replication-competent, the model allows for the study of how viral accessory proteins—which are typically absent in defective models—impact the cell's ability to evade immune surveillance upon reactivation.
This model provides a more accurate representation of the HIV-1 reservoir than traditional defective-virus systems. By incorporating the full viral genome, it enables researchers to better predict how candidate drugs will perform in clinical settings, particularly regarding the interplay between viral reactivation and the host immune response. The inclusion of a GFP-reporter version of the virus also makes this system highly adaptable for medium- to high-throughput drug screening.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.